TandemAI, a Suzhou, and Shangai, China-based supplier of a computational platform to speed up the design and optimization of drug candidates, raised $25m in Seed and pre-Collection A financing.
The spherical was led by OrbiMed and Chengwei Capital. Along side the funding, David Wang, M.D., Ph.D., Senior Managing Director and Accomplice at OrbiMed, who will be a part of TandemAI’s Board of Administrators.
The corporate intends to make use of the funds to advance its proprietary computational platform and growth of its moist lab operations.
The corporate will combine the computational platform with moist labs for biophysics, medicinal chemistry, and biology with a view to speed up the design and optimization of drug candidates for companions.
Led by Jeff He, MBA, co-founder, and CEO, TandemAI is a sophisticated expertise firm devoted to integrating proprietary AI-driven, high-performance computation with large-scale in-house moist lab operations to ship a complete drug discovery answer. The corporate has constructed its networked platform from the bottom up in China to extend the pace of drug discovery and ship cost-effective alternatives to its companions and to the worldwide scientific neighborhood.
Mr. He has greater than 20 years of expertise in senior enterprise management roles at firms, together with most not too long ago at HiFiBiO, the place he served as co-founder and COO, and Harbour BioMed, the place he was a co-founder and CFO. Wei Tang, Ph.D., TandemAI’s COO, was beforehand the CEO of Shanghai ChemPartner and a member of its board of administrators. Earlier than becoming a member of ChemPartner, he served at Merck in a number of senior analysis roles, along with his newest place as a Distinguished Senior Investigator.
TandemAI is quickly establishing moist labs and computing clusters in China.